Ocular Therapeutix (OCUL) analyst forecast and price target
Analyst forecast
Consensus of 12 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Chardan Capital | Maintained | Buy | $23.00 | Aug 4, 2026 |
| Chardan Capital | Maintained | Buy | $23.00 from $21.00 | Jun 25, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 from $21.00 | Jun 18, 2026 |
| Baird | Maintained | Outperform | $30.00 from $24.00 | Jun 18, 2026 |
| RBC Capital | Maintained | Outperform | $30.00 | May 6, 2026 |
| Needham | Maintained | Buy | $18.00 | May 5, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $21.00 | Apr 13, 2026 |
| Clear Street | Maintained | Buy | $28.00 from $21.00 | Mar 3, 2026 |
| Needham | Maintained | Buy | $18.00 from $20.00 | Feb 20, 2026 |
| Chardan Capital | Maintained | Buy | $21.00 | Feb 18, 2026 |
| Chardan Capital | Maintained | Buy | $21.00 | Dec 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $21.00 from $19.00 | Dec 8, 2025 |
| Needham | Maintained | Buy | $20.00 | Dec 8, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $19.00 | Nov 25, 2025 |
| Chardan Capital | Maintained | Buy | $21.00 | Nov 5, 2025 |
| TD Cowen | Maintained | Buy | $20.00 from $14.00 | Oct 30, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $19.00 from $15.00 | Oct 8, 2025 |
| Piper Sandler | Maintained | Overweight | $31.00 from $21.00 | Oct 3, 2025 |
| Baird | Maintained | Outperform | $24.00 from $17.00 | Oct 3, 2025 |
| Chardan Capital | Maintained | Buy | $21.00 | Oct 2, 2025 |
Frequently asked questions
What is the price target for OCUL stock?
The average 12-month analyst price target for Ocular Therapeutix (OCUL) is $26.00, with a high estimate of $30.00 and a low of $23.00, across 3 analysts.
Is OCUL a buy, sell, or hold?
Analysts covering Ocular Therapeutix currently average a Buy rating: 12 buy, 0 hold and 0 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for OCUL?
The average price target of $26.00 implies 154.15% upside from the last price of $10.23.
What is the latest analyst rating on OCUL?
On Aug 4, 2026, Chardan Capital maintained Ocular Therapeutix at Buy with a price target of $23.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.